Nrf2 protects against As(III)-induced damage in mouse liver and bladder

Toxicology and Applied Pharmacology

Volumn 240, Issue 1, 2009, Pages 8-14

  Jiang, Tao ^a,b   Huang, Zheping ^a   Chan, Jefferson Y ^c   Zhang, Donna D ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b FUDAN UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Arsenic; As(III); Nrf2; Oxidative Stress; ROS

Indexed keywords

ARSENIC; DNA; TRANSCRIPTION FACTOR NRF2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLADDER INJURY; BODY WEIGHT; CONTROLLED STUDY; DISEASE SEVERITY; DNA DAMAGE; DNA METHYLATION; EXPOSURE; FLUID INTAKE; LIVER INJURY; LIVER PROTECTION; MOUSE; NONHUMAN; RENAL PROTECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ARSENITES; LIVER DISEASES; MICE; MICE, KNOCKOUT; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; SODIUM COMPOUNDS; URINARY BLADDER DISEASES;

MUS;

EID: 69749108385     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2009.06.010     Document Type: Article

References (47)

1. Aoki Y., Sato H., Nishimura N., Takahashi S., Itoh K., and Yamamoto M. Accelerated DNA adduct formation in the lung of the Nrf2 knockout mouse exposed to diesel exhaust. Toxicol. Appl. Pharmacol. 173 (2001) 154-160
2. Bae D.S., Hanneman W.H., Yang R.S., and Campain J.A. Characterization of gene expression changes associated with MNNG, arsenic, or metal mixture treatment in human keratinocytes: application of cDNA microarray technology. Environ. Health Perspect. 110 Suppl 6 (2002) 931-941
3. Brown K.G., Guo H.R., Kuo T.L., and Greene H.L. Skin cancer and inorganic arsenic: uncertainty-status of risk. Risk Anal. 17 (1997) 37-42
4. Chan K., and Kan Y.W. Nrf2 is essential for protection against acute pulmonary injury in mice. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 12731-12736
5. Chen H., Li S., Liu J., Diwan B.A., Barrett J.C., and Waalkes M.P. Chronic inorganic arsenic exposure induces hepatic global and individual gene hypomethylation: implications for arsenic hepatocarcinogenesis. Carcinogenesis 25 (2004) 1779-1786
6. Cho H.Y., Jedlicka A.E., Reddy S.P., Kensler T.W., Yamamoto M., Zhang L.Y., and Kleeberger S.R. Role of NRF2 in protection against hyperoxic lung injury in mice. Am. J. Respir. Cell Mol. Biol. 26 (2002) 175-182
7. Cho H.Y., Reddy S.P., Yamamoto M., and Kleeberger S.R. The transcription factor NRF2 protects against pulmonary fibrosis. FASEB J. 18 (2004) 1258-1260
8. Chu H.A., and Crawford-Brown D.J. Inorganic arsenic in drinking water and bladder cancer: a meta-analysis for dose-response assessment. Int. J. Environ. Res. Public Health 3 (2006) 316-322
9. Cohen S.M., Shirai T., and Steineck G. Epidemiology and etiology of premalignant and malignant urothelial changes. Scand. J. Urol. Nephrol. Suppl. 105-115 (2000)
10. Das S., Santra A., Lahiri S., and Guha Mazumder D.N. Implications of oxidative stress and hepatic cytokine (TNF-alpha and IL-6) response in the pathogenesis of hepatic collagenesis in chronic arsenic toxicity. Toxicol. Appl. Pharmacol. 204 (2005) 18-26
11. Duyndam M.C., Hulscher T.M., Fontijn D., Pinedo H.M., and Boven E. Induction of vascular endothelial growth factor expression and hypoxia-inducible factor 1alpha protein by the oxidative stressor arsenite. J. Biol. Chem. 276 (2001) 48066-48076
12. Enomoto A., Itoh K., Nagayoshi E., Haruta J., Kimura T., O'Connor T., Harada T., and Yamamoto M. High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol. Sci. 59 (2001) 169-177
13. Hayes J.D., and McMahon M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem. Sci. 34 (2009) 176-188
14. He X., Chen M.G., Lin G.X., and Ma Q. Arsenic induces NAD(P)H-quinone oxidoreductase I by disrupting the Nrf2 × Keap1 × Cul3 complex and recruiting Nrf2 × Maf to the antioxidant response element enhancer. J. Biol. Chem. 281 (2006) 23620-23631
15. Hei T.K., Liu S.X., and Waldren C. Mutagenicity of arsenic in mammalian cells: role of reactive oxygen species. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 8103-8107
16. Hsueh Y.M., Cheng G.S., Wu M.M., Yu H.S., Kuo T.L., and Chen C.J. Multiple risk factors associated with arsenic-induced skin cancer: effects of chronic liver disease and malnutritional status. Br. J. Cancer 71 (1995) 109-114
17. Huang C., Ma W.Y., Li J., and Dong Z. Arsenic induces apoptosis through a c-Jun NH2-terminal kinase-dependent, p53-independent pathway. Cancer Res. 59 (1999) 3053-3058
18. Jones P.A., and Buckley J.D. The role of DNA methylation in cancer. Adv. Cancer Res. 54 (1990) 1-23
19. Kann S., Estes C., Reichard J.F., Huang M.Y., Sartor M.A., Schwemberger S., Chen Y., Dalton T.P., Shertzer H.G., Xia Y., and Puga A. Butylhydroquinone protects cells genetically deficient in glutathione biosynthesis from arsenite-induced apoptosis without significantly changing their prooxidant status. Toxicol. Sci. 87 (2005) 365-384
20. Kayajanian G. Arsenic, cancer, and thoughtless policy. Ecotoxicol. Environ. Saf. 55 (2003) 139-142
21. Kenyon E.M., Del Razo L.M., and Hughes M.F. Tissue distribution and urinary excretion of inorganic arsenic and its methylated metabolites in mice following acute oral administration of arsenate. Toxicol. Sci. 85 (2005) 468-475
22. Kirkpatrick D.S., Dale K.V., Catania J.M., and Gandolfi A.J. Low-level arsenite causes accumulation of ubiquitinated proteins in rabbit renal cortical slices and HEK293 cells. Toxicol. Appl. Pharmacol. 186 (2003) 101-109
23. Kitchin K.T., and Ahmad S. Oxidative stress as a possible mode of action for arsenic carcinogenesis. Toxicol. Lett. 137 (2003) 3-13
24. Knobeloch L.M., Zierold K.M., and Anderson H.A. Association of arsenic-contaminated drinking-water with prevalence of skin cancer in Wisconsin's Fox River Valley. J. Health Popul. Nutr. 24 (2006) 206-213
25. Lamm S.H., Engel A., Kruse M.B., Feinleib M., Byrd D.M., Lai S., and Wilson R. Arsenic in drinking water and bladder cancer mortality in the United States: an analysis based on 133 U.S. counties and 30 years of observation. J. Occup. Environ. Med. 46 (2004) 298-306
26. Lapeyre J.N., Walker M.S., and Becker F.F. DNA methylation and methylase levels in normal and malignant mouse hepatic tissues. Carcinogenesis 2 (1981) 873-878
27. Lau A., Villeneuve N.F., Sun Z., Wong P.K., and Zhang D.D. Dual roles of Nrf2 in cancer. Pharmacol. Res. 58 (2008) 262-270
28. Liu L., Trimarchi J.R., Navarro P., Blasco M.A., and Keefe D.L. Oxidative stress contributes to arsenic-induced telomere attrition, chromosome instability, and apoptosis. J. Biol. Chem. 278 (2003) 31998-32004
29. Mahata J., Ghosh P., Sarkar J.N., Ray K., Natarajan A.T., and Giri A.K. Effect of sodium arsenite on peripheral lymphocytes in vitro: individual susceptibility among a population exposed to arsenic through the drinking water. Mutagenesis 19 (2004) 223-229
30. Navas-Acien A., Silbergeld E.K., Streeter R.A., Clark J.M., Burke T.A., and Guallar E. Arsenic exposure and type 2 diabetes: a systematic review of the experimental and epidemiological evidence. Environ. Health Perspect. 114 (2006) 641-648
31. Pott W.A., Benjamin S.A., and Yang R.S. Antagonistic interactions of an arsenic-containing mixture in a multiple organ carcinogenicity bioassay. Cancer Lett. 133 (1998) 185-190
32. Ramos-Gomez M., Kwak M.K., Dolan P.M., Itoh K., Yamamoto M., Talalay P., and Kensler T.W. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 3410-3415
33. Romach E.H., Zhao C.Q., Del Razo L.M., Cebrian M.E., and Waalkes M.P. Studies on the mechanisms of arsenic-induced self tolerance developed in liver epithelial cells through continuous low-level arsenite exposure. Toxicol. Sci. 54 (2000) 500-508
34. Smith A.H., Lingas E.O., and Rahman M. Contamination of drinking-water by arsenic in Bangladesh: a public health emergency. Bull. World Health Organ. 78 (2000) 1093-1103
35. Smith A.H., Marshall G., Yuan Y., Ferreccio C., Liaw J., von Ehrenstein O., Steinmaus C., Bates M.N., and Selvin S. Increased mortality from lung cancer and bronchiectasis in young adults after exposure to arsenic in utero and in early childhood. Environ. Health Perspect. 114 (2006) 1293-1296
36. Snow E.T., Sykora P., Durham T.R., and Klein C.B. Arsenic, mode of action at biologically plausible low doses: what are the implications for low dose cancer risk?. Toxicol. Appl. Pharmacol. 207 (2005) 557-564
37. Tarantino G., Cabibi D., Camma C., Alessi N., Donatelli M., Petta S., Craxi A., and Di Marco V. Liver eosinophilic infiltrate is a significant finding in patients with chronic hepatitis C. J. Viral Hepatitis 15 (2008) 523-530
38. Tchounwou P.B., Patlolla A.K., and Centeno J.A. Carcinogenic and systemic health effects associated with arsenic exposure - a critical review. Toxicol. Pathol. 31 (2003) 575-588
39. Tseng C.H. An overview on peripheral vascular disease in blackfoot disease-hyperendemic villages in Taiwan. Angiology 53 (2002) 529-537
40. Umemura T., Sai K., Takagi A., Hasegawa R., and Kurokawa Y. Formation of 8-hydroxydeoxyguanosine (8-OH-dG) in rat kidney DNA after intraperitoneal administration of ferric nitrilotriacetate (Fe-NTA). Carcinogenesis 11 (1990) 345-347
41. Umemura T., Kuroiwa Y., Kitamura Y., Ishii Y., Kanki K., Kodama Y., Itoh K., Yamamoto M., Nishikawa A., and Hirose M. A crucial role of Nrf2 in in vivo defense against oxidative damage by an environmental pollutant, pentachlorophenol. Toxicol. Sci. 90 (2006) 111-119
42. Wainfan E., and Poirier L.A. Methyl groups in carcinogenesis: effects on DNA methylation and gene expression. Cancer Res. 52 (1992) 2071s-2077s
43. Walvekar R.R., Kane S.V., Nadkarni M.S., Bagwan I.N., Chaukar D.A., and D'Cruz A.K. Chronic arsenic poisoning: a global health issue - a report of multiple primary cancers. J. Cutan. Pathol. 34 (2007) 203-206
44. Wang X.J., Sun Z., Chen W., Eblin K.E., Gandolfi J.A., and Zhang D.D. Nrf2 protects human bladder urothelial cells from arsenite and monomethylarsonous acid toxicity. Toxicol. Appl. Pharmacol. 225 (2007) 206-213
45. Wang X.J., Sun Z., Chen W., Li Y., Villeneuve N.F., and Zhang D.D. Activation of Nrf2 by arsenite and monomethylarsonous acid is independent of Keap1-C151: enhanced Keap1-Cul3 interaction. Toxicol. Appl. Pharmacol. 230 (2008) 383-389
46. Yang C., Wu J., Zhang R., Zhang P., Eckard J., Yusuf R., Huang X., Rossman T.G., and Frenkel K. Caffeic acid phenethyl ester (CAPE) prevents transformation of human cells by arsenite (As) and suppresses growth of As-transformed cells. Toxicology 213 (2005) 81-96
47. Yu X., and Kensler T. Nrf2 as a target for cancer chemoprevention. Mutat. Res. 591 (2005) 93-102